Sanofi completes Kiadis acquisition
This is a joint press release by Sanofi Foreign
Participations B.V. (the “Offeror”), Sanofi
(“Sanofi”) and Kiadis Pharma N.V.
(“Kiadis”) in connection with the public offer by
the Offeror for all the issued and outstanding ordinary shares in
the capital of Kiadis (the “Offer”). This
announcement does not constitute an offer, or any solicitation of
any offer, to buy or subscribe for any securities. Any offer will
be made only by means of the offer memorandum dated 10 February
2021 (the “Offer Memorandum”), approved by the
Dutch Authority for the Financial Markets (Autoriteit
Financiële Markten) on 10 February 2021 and recognized by the
Belgian Authority for the Financial Markets (Autoriteit voor
Financiële Diensten en Markten) on 11 February 2021. This
announcement is not for release, publication or distribution, in
whole or in part, in or into, directly or indirectly, any
jurisdiction in which such release, publication or distribution
would be unlawful. Terms not defined in this press release will
have the meaning as set forth in the Offer Memorandum.
Sanofi completes Kiadis
acquisition
Paris, France and Amsterdam, The
Netherlands, 16 April 2021 – Sanofi (Euronext: SAN and NYSE: SNY)
and Kiadis (Euronext Amsterdam and Brussels: KDS) today
jointly announce the successful completion of Sanofi’s acquisition
of Kiadis, a clinical-stage biopharmaceutical company developing
next generation ‘off-the-shelf’ NK cell-therapies.
Kiadis’ proprietary platform is based on
allogeneic or ‘off-the-shelf' NK-cells from a healthy donor.
NK-cells seek and identify malignant cancer cells and have broad
application across various tumor types. The platform has the
potential to make products rapidly and economically available for a
broad patient population across a wide range of liquid and solid
tumors, and create synergies with Sanofi’s immuno-oncology
pipeline.
Kiadis’ NK cell-based medicines will be
developed alone and in combination with Sanofi’s existing pipeline
and platforms.
The acquisition continues to build on Sanofi’s
emerging presence in immuno-oncology aligned with the company’s
strategy to pursue best-in-class treatments in defined areas.
As of the Settlement, which has taken place
today, Sanofi holds approximately 95.03% of the issued and
outstanding share capital of Kiadis on a Fully Diluted basis.
Shareholders who have not yet tendered their
Shares will have the opportunity to tender their Shares under the
same terms and conditions applicable to the Offer, during the
Post-Closing Acceptance Period which started on 14 April 2021 and
will end at 17:40 (CET) on 28 April 2021. Sanofi intends to
initiate the Buy-Out in an expeditious manner. Reference is made to
the joint press release by Sanofi and Kiadis dated 13 April
2021.
Upon Settlement the changes to the composition
of the Supervisory Board and Management Board of Kiadis, as
approved by the EGM on 30 March 2021, will become effective.
Dutch Translation / Nederlandse
vertalingParijs, Frankrijk en Amsterdam,
Nederland, 16 april 2021 – Sanofi (Euronext: SAN en NYSE: SNY) en
Kiadis (Euronext Amsterdam en Brussels: KDS) kondigen
gezamenlijk aan de succesvolle afronding van de overname van
Kiadis, een biofarmaceutisch bedrijf gericht op de klinische fase
dat de volgende generatie “off-the-shelf” NK-celtherapieën
ontwikkelt.
Kiadis’ gepatenteerde platform is gebaseerd op
allogene, of ‘off-the-shelf’, NK-cellen van een gezonde donor.
NK-cellen zoeken en identificeren kwaadaardige kankercellen en
hebben een brede toepassingbij verschillende tumortypen. Het Kiadis
platform heeft het potentieel om producten snel en
economischbeschikbaar te maken voor een brede patiëntenpopulatie in
een breed scala aan indicaties tegen bloedkanker en vaste tumoren,
en om synergiën te creëren met de immuno-oncologie pijplijn van
Sanofi.
Kiadis’ NK-celtherapieën zullen als zelfstandige
therapie alsmede in combinatie met de bestaande pijplijn en
platforms van Sanofi worden ontwikkeld.
De overname bouwt voort op Sanofi's opkomende
aanwezigheid in immuno-oncologie, in lijn met de strategie van het
bedrijf om de beste behandelingen in bepaalde gebieden na te
streven.
Vanaf de Overdracht, die vandaag heeft
plaatsgevonden, bezit Sanofi ongeveer 95,03% van het geplaatste en
uitstaande aandelenkapitaal van Kiadis op basis van Volledige
Verwatering.
Aandeelhouders die hun Aandelen nog niet hebben
aangemeld, hebben de mogelijkheid om hun Aandelen aan te melden
onder dezelfde voorwaarden als die van toepassing zijn op het Bod,
tijdens de Na-aanmeldingstermijn die op 14 april 2021 is begonnen
en zal eindigen om 17:40 (CET) op 28 april 2021. Sanofi is
voornemens de Uitkoopprocedure op korte termijn te initiëren.
Verwezen wordt naar het gezamenlijk persbericht van Sanofi en
Kiadis van 13 april 2021.
Bij de Overdracht zullen de wijzigingen in de
samenstelling van de Raad van Commissarissen en de Raad van Bestuur
van Kiadis, zoals goedgekeurd tijdens de BAVA op 30 maart 2021, van
kracht worden.
Dit is een vertaling van het
oorspronkelijke in de Engelse taal opgestelde persbericht en deze
vertaling wordt uitsluitend voor informatieve doeleinden verstrekt.
In geval van verschillen tussen beide versies prevaleert de Engelse
tekst. Aan de vertaling kunnen geen rechten worden
ontleend.
For more information:
Kiadis: Maryann
Cimino, Director Investor Relations& Corporate Affairs Tel: +1
(617) 710 7305 m.cimino@kiadis.comKiadis Media Relations
ContactsLifeSpring Life Sciences
Communication: Leon Melens (Amsterdam) Tel: +31 (20) 538
16 427 lmelens@lifespring.nl Optimum Strategic
Communications: Mary Clark, Supriya Mathur Tel: +44 (203)
950 9144 kiadis@optimumcomms.com |
Sanofi: Sanofi Media
Relations Contact Ashleigh Koss Tel.: +1 (908) 205 2572
ashleigh.koss@sanofi.com Sanofi Investor Relations Contacts
Paris Eva Schaefer-Jansen Arnaud DelepineYvonne
NaughtonSanofi Investor Relations Contacts North
America Felix LauscherFara BerkowitzSuzanne Greco IR main
line:Tel.: +33 (1) 53 77 45 45 ir@sanofi.com |
About Kiadis Founded in 1997,
Kiadis is committed to developing innovative cell-based medicines
for patients with life-threatening diseases. With headquarters in
Amsterdam, The Netherlands, and offices and activities across the
United States, Kiadis is reimagining medicine by leveraging the
natural strengths of humanity and our collective immune system to
source the best cells for life.
Kiadis is listed on the regulated market of
Euronext Amsterdam and Euronext Brussels since July 2, 2015, under
the symbol KDS. Learn more at www.kiadis.com.
About SanofiSanofi is dedicated
to supporting people through their health challenges. It is a
global biopharmaceutical company focused on human health. Sanofi
prevents illness with vaccines and provides innovative treatments
to fight pain and ease suffering. Sanofi stands by the few who
suffer from rare diseases and the millions with long-term chronic
conditions.
With more than 100,000 people in 100 countries,
Sanofi is transforming scientific innovation into healthcare
solutions around the globe.
Sanofi, Empowering Life.
Kiadis forward-looking
statementsCertain statements, beliefs and opinions in this
press release are forward-looking, which reflect Kiadis’ or, as
appropriate, Kiadis’ officers’ current expectations and projections
about future events. By their nature, forward-looking statements
involve a number of known and unknown risks, uncertainties and
assumptions that could cause actual results, performance,
achievements or events to differ materially from those expressed,
anticipated or implied by the forward-looking statements. These
risks, uncertainties and assumptions could adversely affect the
outcome and financial effects of the plans and events described
herein. A multitude of factors including, but not limited to,
changes in demand, regulation, competition and technology, can
cause actual events, performance, achievements or results to differ
significantly from any anticipated or implied development.
Forward-looking statements contained in this press release
regarding past trends or activities should not be taken as a
representation that such trends or activities will continue in the
future. As a result, Kiadis expressly disclaims any obligation or
undertaking to release any update or revisions to any
forward-looking statements in this press release as a result of any
change in expectations or projections, or any change in events,
conditions, assumptions or circumstances on which these
forward-looking statements are based. Neither Kiadis nor its
advisers or representatives nor any of its subsidiary undertakings
or any such person’s officers or employees guarantees that the
assumptions underlying such forward-looking statements are free
from errors nor does either accept any responsibility for the
future accuracy of the forward-looking statements contained in this
press release or the actual occurrence of the anticipated or
implied developments. You should not place undue reliance on
forward-looking statements, which speak only as of the date of this
press release.
Sanofi forward-looking
statementsThis press release contains forward-looking
statements as defined in the Private Securities Litigation Reform
Act of 1995, as amended. Forward-looking statements are statements
that are not historical facts. These statements include projections
and estimates and their underlying assumptions, statements
regarding plans, objectives, intentions and expectations with
respect to future financial results, events, operations, services,
product development and potential, and statements regarding future
performance. Forward-looking statements are generally identified by
the words “expects”, “anticipates”, “believes”, “intends”,
“estimates”, “plans” and similar expressions. Although Sanofi’s
management believes that the expectations reflected in such
forward-looking statements are reasonable, investors are cautioned
that forward-looking information and statements are subject to
various risks and uncertainties, many of which are difficult to
predict and generally beyond the control of Sanofi, that could
cause actual results and developments to differ materially from
those expressed in, or implied or projected by, the forward-looking
information and statements. These risks and uncertainties include
among other things, risks related to Sanofi’s ability to complete
the acquisition on the proposed terms or on the proposed timeline,
the possibility that competing offers will be made, other risks
associated with executing business combination transactions, such
as the risk that the businesses will not be integrated
successfully, that such integration may be more difficult,
time-consuming or costly than expected or that the expected
benefits of the acquisition will not be realized, the uncertainties
inherent in research and development, future clinical data and
analysis, including post marketing, decisions by regulatory
authorities, such as the FDA or the EMA, regarding whether and when
to approve any drug, device or biological application that may be
filed for any such product candidates as well as their decisions
regarding labelling and other matters that could affect the
availability or commercial potential of such product candidates,
the fact that product candidates if approved may not be
commercially successful, the future approval and commercial success
of therapeutic alternatives, Sanofi’s ability to benefit from
external growth opportunities, to complete related transactions
and/or obtain regulatory clearances, risks associated with
intellectual property and any related pending or future litigation
and the ultimate outcome of such litigation, trends in exchange
rates and prevailing interest rates, volatile economic and market
conditions, cost containment initiatives and subsequent changes
thereto, and the impact that COVID-19 will have on us, our
customers, suppliers, vendors, and other business partners, and the
financial condition of any one of them, as well as on our employees
and on the global economy as a whole. Any material effect of
COVID-19 on any of the foregoing could also adversely impact us.
This situation is changing rapidly and additional impacts may arise
of which we are not currently aware and may exacerbate other
previously identified risks. The risks and uncertainties also
include the uncertainties discussed or identified in the public
filings with the SEC and the AMF made by Sanofi, including those
listed under “Risk Factors” and “Cautionary Statement Regarding
Forward-Looking Statements” in Sanofi’s annual report on Form 20-F
for the year ended December 31, 2019. Other than as required by
applicable law, Sanofi does not undertake any obligation to update
or revise any forward-looking information or statements.